Patents by Inventor Shaoqing Chen

Shaoqing Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20250154105
    Abstract: The present invention relates to a polycyclic compound and the use thereof. Specifically, the compound of the present invention has a structure as represented by formula (I), wherein the definitions of each group and each substituent are as described in the description. Also disclosed in the present invention are a method for preparing the compound and the use of the compound in regulating and treating related diseases caused by abnormal activity of YAP/TEAD.
    Type: Application
    Filed: August 12, 2022
    Publication date: May 15, 2025
    Inventors: Apeng LIANG, Jun LI, Yusheng WU, Shaoqing CHEN, Guangbin LIU, Zhou YIN, Shengli DONG, Meihua LI
  • COMPOUND FOR DEGRADING EGFR PROTEIN AND USE THEREOF
    Publication number: 20250129086
    Abstract: The present invention relates to a compound for degrading an EGFR protein and the use thereof. Specifically, the present invention relates to a compound as represented by formula (I), and the definitions of each group and each substituent are as described in the description. The present invention further relates to the use of the compound in the preparation of a drug for regulating the activity of an EGFR tyrosine kinase or treating EGFR-related diseases, particularly non-small cell lung cancer.
    Type: Application
    Filed: November 17, 2022
    Publication date: April 24, 2025
    Inventors: APeng LIANG, Yusheng WU, Shaoqing CHEN, Jun LI, Shunxun HAN, Shengli DONG, Chengshan NIU
  • COMPOUND USED AS SHP2 INHIBITOR AND USE THEREOF
    Publication number: 20240190887
    Abstract: The present invention relates to a compound used as an SHP2 inhibitor and the use thereof. Specifically, the compound of the present invention has a structure as represented by formula I?, wherein the definitions of each group and each substituent are as described in the description. The compound has a high inhibitory effect on the activity of the SHP2 phosphatase, and can be used for preventing or treating SHP2-related diseases.
    Type: Application
    Filed: July 7, 2022
    Publication date: June 13, 2024
    Inventors: Chengshan NIU, Maolin ZHENG, Apeng LIANG, Shaoqing CHEN, Jun LI, Yusheng WU
  • 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF
    Publication number: 20240109863
    Abstract: The present invention provides a 2-pyridone derivative having a structure represented by formula I, or a stereoisomer or pharmaceutically acceptable salt thereof. Activity experiment results show that the 2-pyridone derivative provided in the present invention has higher activity and selectivity, and can be used to treat thyroid hormone receptor-related diseases.
    Type: Application
    Filed: December 28, 2021
    Publication date: April 4, 2024
    Applicants: KPC PHARMACEUTICALS, INC, SHANGHAI KUNHENG PHARMA-TECH CO., LTD
    Inventors: Hejun LV, Peng WANG, Fei GUO, Shaoqing CHEN, Junfeng LIU
  • Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators
    Publication number: 20180298026
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Application
    Filed: June 18, 2018
    Publication date: October 18, 2018
    Inventors: Nidhl Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Ciara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Tetrahydro-benzodiazepinones
    Patent number: 10053431
    Abstract: Disclosed are compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R1, R2, R3, R4 and R5 are as described in this application, and methods of using said compounds in the treatment of cancer.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: August 21, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Shaoqing Chen, Andrew F. Donnell, Robert Francis Kester, Kang Le, Yan Lou, Christophe Michoud, Stacy Remiszewski, Kenneth C. Rupert, Martin Weisel
  • Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators
    Patent number: 10023589
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: July 17, 2018
    Assignees: Hoffmann-La Roche Inc., Roche Palo Alto LLC
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Clara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Thienopyrimidine compounds
    Patent number: 9701691
    Abstract: The present invention relates to the use of novel compounds of Formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: July 11, 2017
    Assignee: Hoffman-La Roche Inc.
    Inventors: Shaoqing Chen, Johannes Cornelius Hermann, Nam T. Le, Matthew C. Lucas, Fernando Padilla
  • Substituted sulfonamide compounds
    Patent number: 9580411
    Abstract: The invention is concerned with the compounds of formula (I): and salts thereof, wherein X, Y, Z, R1, R2, R3, R3?, R4, R5 and R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of Formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: February 28, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christine E. Brotherton-Pleiss, Huifen Chen, Shaoqing Chen, Zhi Chen, Shawn David Erickson, Anthony Estrada, Kyungjin Kim, Hongju Li, Allen John Lovey, Joseph P. Lyssikatos, Yimin Qian, Sung-Sau So, Peter Michael Wovkulich, Lin Yi
  • TETRAHYDRO-BENZODIAZEPINONES
    Publication number: 20160272596
    Abstract: Disclosed are compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R1, R2, R3, R4 and R5 are as described in this application, and methods of using said compounds in the treatment of cancer.
    Type: Application
    Filed: November 14, 2014
    Publication date: September 22, 2016
    Inventors: Shaoqing Chen, Andrew F. Donnell, Robert Francis Kester, Kang Le, Yan Lou, Christophe Michoud, Stacy Remiszewski, Kenneth C. Rupert, Martin Weisel
  • PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
    Publication number: 20160207936
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Application
    Filed: December 18, 2015
    Publication date: July 21, 2016
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Ciara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators
    Patent number: 9255110
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: February 9, 2016
    Assignees: ROCHE PALO ALTO LLC, HOFFMANN-LA ROCHE INC.
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Clara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • SUBSTITUTED SULFONAMIDE SOLUTIONS
    Publication number: 20150197509
    Abstract: The invention is concerned with the compounds of formula (I): and salts thereof, wherein X, Y, Z, R1, R2, R3, R3?, R4, R5 and R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of Formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: March 27, 2015
    Publication date: July 16, 2015
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC.
    Inventors: Christine E. BROTHERTON-PLEISS, Huifen CHEN, Shaoqing CHEN, Zhi CHEN, Shawn David ERICKSON, Anthony ESTRADA, Kyungjin KIM, Hongju LI, Allen John LOVEY, Joseph P. LYSSIKATOS, Yimin QIAN, Sung-Sau SO, Peter Michael WOVKULICH, Lin YI, I
  • PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
    Publication number: 20140303149
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Application
    Filed: April 2, 2014
    Publication date: October 9, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Clara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Detection method and apparatus for multiple-input multiple-output single carrier block transmission system
    Patent number: 8811145
    Abstract: The present invention discloses a detection method, a receiver, and an apparatus in a multiple-input multiple-output single-carrier block transmission system. Through sorted QR decomposition (Sorted QR Decomposition, SQRD) decomposition based on a minimum mean squared error (Minimum Mean Squared Error, MMSE) criterion, an matrix inverse operation in minimum mean squared error equalization is avoided, and complexity is significantly reduced. In addition, through layer-by-layer soft interference cancellation detection after the SQRD decomposition and further iterative processing, better detection performance may be obtained. Especially, inter-stream interference suppression may be performed in first iteration.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: August 19, 2014
    Assignee: Huawei Technologies Co., Ltd.
    Inventors: Wenjin Wang, Shaoqing Chen, Xiqi Gao, Long Qin, Dongming Wang
  • Pyrrolopyrazine kinase inhibitors
    Patent number: 8658646
    Abstract: The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: February 25, 2014
    Assignee: Hoffmann-LaRoche Inc.
    Inventors: Shaoqing Chen, Javier de Vicente Fidalgo, Matthew Michael Hamilton, Johannes Cornelius Hermann, Joshua Kennedy-Smith, Hongju Li, Allen John Lovey, Matthew C. Lucas, Kin-Chun Thomas Luk, Stephen M. Lynch, Counde O'yang, Fernando Padilla, Ryan Craig Schoenfeld, Achyutharao Sidduri, Michael Soth, Ce Wang, Peter Michael Wovkulich, Xiaohu Zhang
  • PYRROLOPYRAZINE KINASE INHIBITORS
    Publication number: 20130059834
    Abstract: The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.
    Type: Application
    Filed: August 31, 2012
    Publication date: March 7, 2013
    Inventors: Shaoqing Chen, Javier de Vicente Fidalgo, Matthew Michael Hamilton, Johannes Cornelius Hermann, Joshua Kennedy-Smith, Hongju Li, Allen John Lovey, Matthew C. Lucas, Kin-Chun Thomas Luk, Stephen M. Lynch, Counde O'yang, Fernando Padilla, Ryan Craig Schoenfeld, Achyutharao Sidduri, Michael Soth, Ce Wang, Peter Michael Wovkulich, Xiaohu Zhang
  • DETECTION METHOD AND APPARATUS FOR MULTIPLE-INPUT MULTIPLE-OUTPUT SINGLE-CARRIER BLOCK TRANSMISSION SYSTEM
    Publication number: 20120327757
    Abstract: The present invention discloses a detection method, a receiver, and an apparatus in a multiple-input multiple-output single-carrier block transmission system. Through sorted QR decomposition (Sorted QR Decomposition, SQRD) decomposition based on a minimum mean squared error (Minimum Mean Squared Error, MMSE) criterion, an matrix inverse operation in minimum mean squared error equalization is avoided, and complexity is significantly reduced. In addition, through layer-by-layer soft interference cancellation detection after the SQRD decomposition and further iterative processing, better detection performance may be obtained. Especially, inter-stream interference suppression may be performed in first iteration.
    Type: Application
    Filed: July 9, 2012
    Publication date: December 27, 2012
    Inventors: Wenjin WANG, Shaoqing Chen, Xiqi Gao, Long Qin, Dongming Wang
  • PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
    Publication number: 20120015962
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Application
    Filed: July 12, 2011
    Publication date: January 19, 2012
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Adreas Kuglstatter, Sharada Shenvi Labadie, Clara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Substituted hydantoins
    Patent number: 8063085
    Abstract: The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.
    Type: Grant
    Filed: December 10, 2008
    Date of Patent: November 22, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Shaoqing Chen, Nicholas J. S. Huby, Norman Kong, John Anthony Moliterni, Omar Jose Morales